Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 4/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639289 | 0.83 | ESR1 (0.36) | ESR1ESR2 | |
| SCHEMBL25098855 | 0.81 | AKT1 (0.40) | ESR1ESR2HTR2AHTR2CHTR2B | |
| SCHEMBL14084760 | 0.75 | CYP1A2 (0.48) | ESR1ESR2HTR2AHTR2CHTR2B | |
| SCHEMBL20469944 | 0.73 | HTR2A (0.40) | HTR2AHTR2CHTR2BGRM4AKT1 | |
| SCHEMBL23661911 | 0.72 | CYP1A2 (0.36) | ESR1ESR2 | |
| SCHEMBL20375682 | 0.72 | NOS1 (0.33) | ESR1ESR2HTR2AHTR2CHTR2B | |
| SCHEMBL21497378 | 0.71 | HTR2A (0.43) | ESR1ESR2HTR2AHTR2CHTR2B | |
| SCHEMBL24185043 | 0.71 | KDM4E (0.30) | — | |
| SCHEMBL23008292 | 0.70 | HTR2A (0.42) | ESR1ESR2HTR2AHTR2CHTR2B | |
| SCHEMBL12026472 | 0.70 | MAPT (0.44) | GRM4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870624-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC11 | ESR1 4777/4885ESR2 4239/4885HTR2A 4413/4885 |
| US-10870624-B2 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC2 | ESR1 4734/4885ESR2 3681/4885HTR2A 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.